Vascepa

ESC 2019 – Amarin hopes for guideline boost despite regulatory delay
ESC 2019 – Amarin hopes for guideline boost despite regulatory delay
EP Vantage
Amarin
Vascepa
ESC
European Society of Cardiology
Flag link:
Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting
Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting
Fierce Pharma
Amarin
Vascepa
advisory panels
FDA
Flag link:
Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom
Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom
Endpoints
FDA
Amarin
Vascepa
advisory panels
earnings
Flag link:
Acasti sits pretty as raise brings $400M for Amarin
Acasti sits pretty as raise brings $400M for Amarin
BioWorld
Amarin
Vascepa
FDA
Acasti
Flag link:
Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push
Amarin raises sales guidance for heart drug Vascepa, hires more sales reps for larger marketing push
Stat
Amarin
Vascepa
FDA
hirings
drug reps
Flag link:
Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?
Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?
Endpoints
Amarin
Vascepa
FDA
Flag link:
Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in
Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in
Fierce Pharma
Amarin
Vascepa
Flag link:
Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up
Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up
Endpoints
Amarin
Vascepa
FDA
M&A
Flag link:
Diabetes group nods to Vascepa, sending Amarin stock higher
Diabetes group nods to Vascepa, sending Amarin stock higher
Biopharma Dive
ADA
Vascepa
Amarin
diabetes
Flag link:
Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate
Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate
Stat
Amarin
Vascepa
American College of Cardiology
Flag link:
ACC 2019 preview – Bayer hopes for heart failure panache
ACC 2019 preview – Bayer hopes for heart failure panache
EP Vantage
Bayer
heart failure
Amarin
Esperion
ACC
Vascepa
bempedoic acid
Flag link:
Is Amarin Sitting on a Goldmine?
Is Amarin Sitting on a Goldmine?
Motley Fool
Vascepa
Amarin
Flag link:
Pharma's 2019 Prognosis Hinges on These Key Themes
Pharma's 2019 Prognosis Hinges on These Key Themes
Bloomberg
drug pricing
Amarin
Vascepa
IPOs
cancer
Flag link:
2 Biotech Stocks Poised for Big Gains in 2019
2 Biotech Stocks Poised for Big Gains in 2019
Motley Fool
Amarin
Vascepa
Novavax
ResVax
Flag link:
Amarin raises $200M ahead of Vascepa push
Amarin raises $200M ahead of Vascepa push
BioCentury
Amarin
Vascepa
Flag link:
Amarin's Vascepa trial stirs data debate as stock drops 10%
Amarin's Vascepa trial stirs data debate as stock drops 10%
Biopharma Dive
Amarin
Vascepa
Flag link:
Amarin's Fish-Oil-Derived Drug Shows Great Promise — With Big Caveats
Amarin's Fish-Oil-Derived Drug Shows Great Promise — With Big Caveats
Forbes
Amarin
Vascepa
Flag link:
Why Amarin Stock Jumped 28% in October -- and Why a Bigger Move Could Come Soon
Why Amarin Stock Jumped 28% in October -- and Why a Bigger Move Could Come Soon
Motley Fool
Amarin
Vascepa
Flag link:
Experts question Amarin's early touting of Vescepa data ahead of detailed results
Experts question Amarin's early touting of Vescepa data ahead of detailed results
Endpoints
Amarin
Vascepa
heart disease
Flag link:
[video+transcript] How Big Could Amarin's Vascepa Be?
[video+transcript] How Big Could Amarin's Vascepa Be?
Motley Fool
Vascepa
Amarin
Flag link:

Pages